These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 25753434)

  • 1. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
    Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
    J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
    Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
    Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
    van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
    Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
    Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
    J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
    Gupta A; Williams BR; Hanash SM; Rawwas J
    Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
    Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
    BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.